Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Eisai, a Japanese pharmaceutical company, receives New Drug Approval for its in-house developed anticancer agent Halaven. The China National Medical Products Administration (NMPA) has approved the...